<- Go Home

RHS Limited

RHS Limited develops and markets biotechnology solutions. It offers EmbryoCellect, a preimplantation genetic screening solution; DOPlify, a whole genome amplification kit; and PG-Seq, a NGS workflow solution for preimplantation genetic testing for aneuploidy and preimplantation genetic testing for monogenic disorders. The company also provides preimplantation genetic screening and whole genome amplification services. RHS Limited was formerly known as Reproductive Health Science Limited and changed its name to RHS Limited in June 2017. The company was founded in 1980 and is based in Thebarton, Australia. As of June 14, 2018, RHS Limited operates as a subsidiary of Revvity, Inc.

Market Cap

AUD 24.7M

Volume

291.6K

Cash and Equivalents

AUD 852.6K

EBITDA

-AUD 2.0M

Tax Rate Collected

N/A

Tax Rate Ratio

N/A

Gross Profit

AUD 131.1K

Profit Margin

62.27%

52 Week High

AUD 0.28

52 Week Low

AUD 0.10

Dividend

N/A

Price / Book Value

36.06

Price / Earnings

-11.80

Price / Tangible Book Value

38.97

Enterprise Value

N/A

Enterprise Value / EBITDA

N/A

Operating Income

-AUD 2.0M

Return on Equity

207.10%

Return on Assets

-82.60

Cash and Short Term Investments

AUD 852.6K

Debt

AUD 118.9K

Equity

AUD 685.9K

Revenue

AUD 210.5K

Unlevered FCF

-AUD 1.2M

Sector

Biotechnology

Category

N/A

Hedge Funds that own this stock

PREMIUM

Upgrade to Yellowbrick Premium to unlock the Professional Funds that own this company (and many other perks).

Upgrade to Yellowbrick Premium

Yellowbrick Portfolios that own this stock

PREMIUM

Upgrade to Yellowbrick Premium to unlock the Yellowbrick portfolios that own this company (and many other perks).

Upgrade to Yellowbrick Premium

Company Stock Pitches